| Literature DB >> 27756099 |
Hirotsugu Nagase1,2, Tomohira Takeoka1,2, Shinya Urakawa1,2, Akiko Morimoto-Okazawa1, Atsunari Kawashima1, Kota Iwahori1, Shuji Takiguchi2, Hiroyoshi Nishikawa3, Eiichi Sato4, Shimon Sakaguchi5, Masaki Mori2, Yuichiro Doki2, Hisashi Wada1.
Abstract
Regulatory T cells (Tregs) have an immunosuppressive role in the tumor microenvironment. Since effector Tregs (eTregs), which have highly suppressive functions, are located in a subpopulation of Foxp3+ CD4+ Tregs, the TCR-inducible costimulatory receptor (ICOS) was applied as a marker of eTregs that infiltrated gastric cancer tissue and the induction pathway of ICOS+ Foxp3+ cells was analyzed by flow cytometry and immunohistochemistry. In tumor-infiltrating lymphocytes (TILs), ICOS+ Foxp3+ CD4+ T cells were abundantly observed in the late stages of gastric cancer. ICOS+ CD4+ TILs exhibited the ability to produce IL-10, but not IFN-γ, TNF, or IL-17 and also to suppress the proliferation of CFSE-labeled responder CD8+ T cells. With the agonistic ICOS-L protein (rICOS-L Ig), ICOS+ Foxp3+ cells were efficiently induced from naive CD4+ T cells under a stimulation with TGF-β and CD3/CD28 mAbs. Furthermore, when A*0201 PBMCs were cultured with the CMV or Melan-A antigenic peptide and rICOS-L Ig, the induction of CMV or Melan-A tetramer-binding CD8+ T cells, respectively, was inhibited. The expression of ICOS in Foxp3+ cells was closely related to plasmacytoid dendritic cells (pDCs) and their expression of ICOS-L and TLR9 as well as Helicobacter pylori infection. Collectively, our results demonstrate the potential of ICOS as a promising target for direct Treg-targeting therapeutic agents for gastric cancer, and that of eradicating therapy for H. pylori as an indirect immune therapy for gastric cancer.Entities:
Keywords: Foxp3; ICOS ligand; TIL; TLR9; pDC
Mesh:
Substances:
Year: 2016 PMID: 27756099 DOI: 10.1002/ijc.30475
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396